UK Life Sciences Leadership & Appointments
Leadership changes can shape the direction of biotechnology, pharmaceutical and laboratory technology organisations. This category covers material appointments, departures and governance developments across the UK life sciences sector.
Synexa Life Sciences Appoints COO and CSO in Leadership Changes
Synexa Life Sciences has appointed Jordyn van Teylingen as Chief Operating Officer and Natalie Strickland as Chief Scientific Officer. Van Teylingen, previously Co-Chief Scientific Officer, will oversee operational delivery, digital initiatives and internal systems, while Strickland takes sole responsibility for scientific leadership. The company provides biomarker and bioanalytical services for pharmaceutical, biotechnology and CRO clients.
Catalent Appoints Wetteny Joseph to Lead Pharma and Consumer Health
Catalent appointed Wetteny Joseph as Group President, Pharma and Consumer Health, effective 2 November 2026. He succeeds Aris Gennadios and will lead a business covering oral drug delivery and manufacturing, alongside consumer health solutions. Joseph rejoins Catalent from Zoetis, where he was Executive Vice President and Chief Financial Officer, and previously held senior finance and clinical supply leadership positions at Catalent.
EnteroBiotix Appoints Former GSK Medical Chief Murray Stewart to Board
EnteroBiotix announced the appointment of Dr Murray Stewart to its board of directors on 2 November 2026. Stewart previously served as Chief Medical Officer at GSK and Rhythm Pharmaceuticals and held research and development leadership roles at Novelion Therapeutics. EnteroBiotix said his clinical and regulatory experience will support development of its microbiome therapeutics, including the ongoing Phase 2b RISE study in irritable bowel syndrome with constipation.
ViiV Healthcare CEO Deborah Waterhouse Leaves to Lead CSL, Lynn Baxter Named Successor
ViiV Healthcare CEO Deborah Waterhouse, who has led the company since 2017, is leaving to become CEO of CSL from 1 February 2027. GSK Europe president Lynn Baxter will take over as ViiV CEO from 1 November.
Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor to Board
Mestag Therapeutics has appointed Replimune co-founder Philip Astley-Sparke and former Array BioPharma CMO Victor Sandor to its board. The company is running the Phase 1 STARLYS trial of its bispecific antibody MST-0312 in advanced solid tumours.